Custom News

All types

All types

News

Press releases - Regulatory

Press releases - Non regulatory

All years

All years

2019

2018

2017

2015

2010

2009

  • ISOFOL ANNOUNCES THAT AN ABSTRACT HAS BEEN ACCEPTED FOR PRESENTATION AT THE 2019 ESMO CONGRESS

    Non regulatory press release

    GOTHENBURG, Sweden, September 12, 2019 - Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Nyhetsbrev

    News

    Sed tincidunt diam non arcu convallis condimentum. Mauris aliquam, leo ut fermentum convallis, sapien ipsum…

  • Q4 report

    Regulatory press release

    Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean tempus, mauris eu convallis porttitor, leo…

  • Isofol Announces Management Team Evolution with Appointment of Dr. Roger Tell as Chief Medical Officer

    News

    Isofol Announces Management Team Evolution with Appointment of Dr. Roger Tell as Chief Medical Officer…

  • Isofol Announces Recent Advisory Board Meeting Covering Development Plan for arfolitixorin

    News

    Isofol Announces Recent Advisory Board Meeting Covering Development Plan for arfolitixorin GOTHENBURG, Sweden, July 15,…

  • Isofol Announces Recent Advisory Board Meeting Covering Development Plan for arfolitixorin

    News

    GOTHENBURG, Sweden, July 15, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol Receives Clinical Use Patent Approval in the United States for Drug Candidate arfolitixorin

    Regulatory press release

    GOTHENBURG, Sweden, June 25, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol Receives Clinical Use Patent Approval in the United States for Drug Candidate arfolitixorin

    News

    Isofol Receives Clinical Use Patent Approval in the United States for Drug Candidate arfolitixorin GOTHENBURG,…

  • Isofol Receives Clinical Use Patent Approval in the United States for Drug Candidate arfolitixorin

    Regulatory press release

    GOTHENBURG, Sweden, June 25, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol Announces Election of Three New Board Members

    News

    Isofol Announces Election of Three New Board Members GOTHENBURG, Sweden, June 10, 2019 – Isofol…

  • Isofol Announces Election of Three New Board Members

    News

    GOTHENBURG, Sweden, June 10, 2019 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL),…

  • Isofol’s drug candidate arfolitixorin receives clinical patent approval in the United States

    News

    Isofol’s drug candidate arfolitixorin receives clinical patent approval in the United States GOTHENBURG, Sweden, May…

  • Isofol’s drug candidate arfolitixorin receives clinical patent approval in the United States

    Regulatory press release

    GOTHENBURG, Sweden, May 21, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol Reports 58 % Overall Response Rate

    News

    Isofol Reports 58 % Overall Response Rate in Patients with Metastatic Colorectal Cancer in Phase…

  • Isofol Reports 58 % Overall Response Rate in Patients with Metastatic Colorectal Cancer in Phase 1/2a Open Label Extension Study with arfolitixorin

    Regulatory press release

    GOTHENBURG, Sweden, May 8, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Poadcast – “The Cancer Gene”

    News

    Listen to recent episode from The Cancer Gene podcast features Anders Rabbe, CEO of Isofol,…

  • En ny patentansökan för IRLAB:s läkemedelskandidat IRL752 har publicerats av World Intellectual Property Organization, WIPO

    Regulatory press release

    RLAB meddelade idag att World Intellectual Property Organization, WIPO, har offentliggjort en ny patentansökan för…

  • Isofol Reports All Employees Participate in Newly Created Share Warrant Program

    News

    GOTHENBURG, Sweden, February 1, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol has participated in the Empowered Patient Podcast

    News

    In honor of World Cancer Day on February 4, we would like to share a…

  • Isofol Reports Early Tumor Shrinkage in Patients with Colorectal Cancer in Phase 1/2a Open Label Extension Study with arfolitixorin

    News

    GOTHENBURG, Sweden, January 17, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • First patient enrolled in Isofol’s Pivotal Phase 3 AGENT study in 1st line metastatic colorectal cancer

    News

    GOTHENBURG, Sweden, December 18, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL)…

  • Isofol Strengthens Executive Management Team with the Appointment of Roger Tell, MD, PhD, as Chief Scientific Officer and Senior Vice President of Clinical Development

    News

    GOTHENBURG, Sweden, November 19, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol Announces the Appointment of Robert Marchesani as an Advisor to its Board of Directors

    News

    GOTHENBURG, Sweden, November 16, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),…

  • Isofol Announces Initiation of a Pivotal Phase 3 Clinical Trial of arfolitixorin for the Treatment of Metastatic Colorectal Cancer

    News

    GOTHENBURG, Sweden, November 15, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL)…

  • Isofol presents a poster at ESMO 2018 Congress in Germany

    News

    Isofol is attending the ESMO 2018 Congress in Germany, which is taking place between October…

  • New Chairman and extended board at Isofol Medical AB (publ)

    News

    Isofol Medical AB (publ), developing arfolitixorin as treatment for advanced colorectal cancer is calling an…

  • Patent approved in the United States for Isofol’s drug candidate arfolitixorin

    News

    The patent now approved in the United States expires in 2037 and covers both the…

  • DNB initiates monitoring of Isofol

    News

    The Norwegian Bank (DNB) has initiate the monitoring of Isofol Medical AB.     For…

  • Redeye and Isofol are inviting to the live broadcast of pre-ASCO on May 28th

    News

    In connection to this year’s major cancer congress ASCO (American Society of Clinical Oncology) in…

  • Redeye and Isofol are inviting to the live broadcast of pre-ASCO on May 28th

    News

    In connection to this year's major cancer congress ASCO (American Society of Clinical Oncology (https://www.asco.org/)) in…

  • Isofol announces that an abstract with new research resultshas been published for this year’s ASCO congress in Chicago

    Regulatory press release

    Isofol Medical AB (publ) announces that a scientific abstract has been published for this year's…

  • Isofol reports FDAs feedback from the ongoing special protocol assessment (SPA) process

    Regulatory press release

    In March 2018, Isofol Medical AB (publ) submitted a Special Protocol Assessment (SPA) to the…

  • Invitation to a specialist investor event focusing on late-stage drugs for colorectal cancer with Redeye and Isofol Medical

    News

    On April 10th, Redeye will organize an investor specialist event focusing on late-stage drugs aimed…

  • Isofol Medical adopts the World Health Organization recommended name (INN) arfolitixorin for Modufolin®

    News

    Isofol Medical AB (publ) today announce that the company will in the future be adopting…

  • Isofol to present at the 10th Annual Biotech Showcase Conference

    News

    January 4 2017 Isofol Medical AB (publ), a clinical oncology company, announces that Chief Executive…

  • Isofol attends the French-Swedish Life Science Day 2017

    News

    The French-Swedish Life Science Day 2017 conference gathers highly innovative biotech companies from Sweden, French…

  • ­­­Isofol appoints Gustaf Albèrt as Chief Financial Officer

    Regulatory press release

    Isofol Medical AB (publ) has recruited Gustaf Albèrt as Chief Financial Officer. With extensive experience…

  • Isofol has initiated five additional study sites in the ISO-CC-005 study in which Modufolin® is evaluated in colorectal cancer

    News

    Isofol Medical AB (publ) announced today that the last one of five additional study sites…

  • Isofol Announces Publication of an Abstract for the 2017 ASCO Annual Meeting

    News

    Isofol Medical AB (publ) announces publication of an abstract regarding failure rate of standard rescue…

  • Isofol accepted for presentation of abstract at the 2017 ASCO annual meeting

    News

    Isofol Medical AB (publ) announces that an abstract has been accepted to be presented at…

  • Invitation: Isofol will present it’s contemplated IPO in Stockholm on March 29

    News

    In connection with the contemplated IPO of Isofol Medical on Nasdaq First North Premier, we…

  • Invitation: Isofol will present it’s contemplated IPO in Göteborg on March 22

    News

    In connection with the contemplated IPO of Isofol Medical on Nasdaq First North Premier, we…

  • ISOFOLS BOKSLUTSKOMMUNIKÉ JANUARI – DECEMBER 2016

    News

    Read more here –>

  • ISOFOL ANNOUNCES ITS INTENTION TO LIST ON NASDAQ FIRST NORTH PREMIER

    News

    For a complete press release follow the link https://dev.isofolmedical.com/ipo For additional information, please contact: Anders…

  • ISOFOL ANSÖKER OM VIKTIGT PATENT I USA

    News

    Isofol Medical AB (publ) meddelar att en ny patentansökan lämnats in, den 14 februari, 2017,…

  • EXTRA BOLAGSSTÄMMA I ISOFOL MEDICAL AB

    News

    Aktieägarna i Isofol Medical AB (publ) kallas härmed till extra bolagsstämma onsdagen den 22 februari…

  • SCRIP INTELLIGENCE, A LEADING SOURCE OF NEWS AND STRATEGIC ANALYSIS FOR THE GLOBAL PHARMACEUTICAL INDUSTRY, PUBLISH ARTICLE ABOUT ISOFOL MEDICAL AB’S LEAD CANDIDATE MODUFOLIN®, AND THE UPCOMING PIVOTAL PHASE III STUDY IN METASTATIC COLORECTAL CANCER

    News

    John Davis, journalist and editor for more than 30 years, of Scrip Intelligence recently interviewed…

  • Stockholm Corporate Finance Life Science Day 2015

    News

    Isofol’s Chief Scientific Officer, Anders Vedin presented at the Stockholm Corporate Finance Life Science Day…

  • Stort intresse för göteborgsk life science

    News

    (Swedish) Pressklipp Kemivärlden Biotech / Chemicalnet Behandling av alkoholberoende, cancerläkemedel som testas på patienter och…

  • Isofol tests new medicine against cancer

    News

    (Swedish) Pressklipp Dagens Industri –  Isofol testar ny medicin mot cancer I början av januari…